- ¥6bn
- ¥1bn
- ¥8m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 827.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.6% | ||
| Return on Equity | -18.52% | ||
| Operating Margin | -14092.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 97.28 | 100.73 | 625.78 | 316.82 | 7.59 | 319 | 319 | -47.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 16th, 2015
- Public Since
- June 28th, 2023
- No. of Shareholders
- 8,076
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 43,301,765
- Address
- 6F, Ark Ginza Bldg., 7-17-2, Ginza, MINATO-KU, 105-0012
- Web
- https://www.noile-immune.com/
- Phone
- +81 358437819
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4893
Q1 2025 Noile-Immune Biotech Inc Earnings Release
Dividend For 4893.T - 0.0000 JPY
Dividend For 4893.T - 0.0000 JPY
Similar to 4893
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Noile-Immune Biotech share price?
As of Today at 22:20 UTC, shares in Noile-Immune Biotech are trading at ¥145. This share price information is delayed by 15 minutes.
How has the Noile-Immune Biotech share price performed this year?
Shares in Noile-Immune Biotech last closed at ¥145 and the price had moved by -9.94% over the past 365 days. In terms of relative price strength the Noile-Immune Biotech share price has underperformed the Nikkei 225 Index by -5.09% over the past year.
What are the analyst and broker recommendations for Noile-Immune Biotech?
The overall consensus recommendation for Noile-Immune Biotech is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Noile-Immune Biotech dividend yield?
Noile-Immune Biotech does not currently pay a dividend.
Does Noile-Immune Biotech pay a dividend?
Noile-Immune Biotech does not currently pay a dividend.
When does Noile-Immune Biotech next pay dividends?
Noile-Immune Biotech does not currently pay a dividend.
How do I buy Noile-Immune Biotech shares?
To buy shares in Noile-Immune Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Noile-Immune Biotech?
As of the previous close price of ¥145, shares in Noile-Immune Biotech had a market capitalisation of ¥6bn.
Where are Noile-Immune Biotech shares listed?
Here are the trading details for Noile-Immune Biotech:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4893
What kind of share is Noile-Immune Biotech?
Based on an overall assessment of its quality, value and momentum Noile-Immune Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Noile-Immune Biotech share price forecast for 2025?
The analyst consensus target price for shares in Noile-Immune Biotech is ¥449. That is 209.86% above the last closing price of ¥145.
Analysts covering Noile-Immune Biotech currently have a consensus Earnings Per Share (EPS) forecast of -¥29 for the next financial year.
Find out moreWhat is the trend in the Noile-Immune Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Noile-Immune Biotech. Over the past six months, its share price has outperformed the Nikkei 225 Index by +0.5%.
As of the last closing price of ¥145, shares in Noile-Immune Biotech were trading -19.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Noile-Immune Biotech PE Ratio?
The Noile-Immune Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥145.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Noile-Immune Biotech?
We do not have data on Noile-Immune Biotech's directors